Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of prior MK-5172-treated chronic hepatitis C subjects
NL-OMON43992Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of grazoprevir in hepatitis C virus infection (2 arms), sponsored by Merck & Co. Primary endpoints: Durability of sustained virologic response, Long-term antiviral resistance and 1 more. Started Aug 2015; status: active, not recruiting.
02
Drugs
grazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON43992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43992.